Estimation of the Relative Contribution of Postprandial Glucose Exposure to Average Total Glucose Exposure in Subjects with Type 2 Diabetes

Table 1

Patient demographics and baseline characteristics.

	Vildagliptin monotherapy; ()	Vildagliptin/metformin combination therapy; ()
Age (years)	54.7 ± 0.2	56.8 ± 0.2
Gender: male, (%)	1435 (48)	1497 (52)
BMI (kg/m^2)	30.8 ± 0.1	31.5 ± 0.1
Diabetes duration (years)	2.3 ± 0.1	5.2 ± 0.1
HbA1c (%)	8.4 ± 0.02	7.9 ± 0.02
eAG (mmol/L)	10.8 ± 0.03	10.0 ± 0.03
FPG (mmol/L)	9.9 ± 0.1	9.8 ± 0.1
aPPG (mmol/L)	0.9 ± 0.04	0.2 ± 0.04

Data are presented as mean ± SE unless otherwise stated.
aPPG, apparent postprandial glucose; BMI, body mass index; eAG, estimated average glucose; FPG, fasting plasma glucose; HbA1c, glycated haemoglobin; SE, standard error.